TECENTRIQ – atezolizumab 840 mg/14 mL (60 mg/mL) and 1200 mg/20 mL (60 mg/mL) intravenous solution

Genentech Inc

liver cell carcinoma; non-small cell lung cancer; malignant melanoma with BRAF V600 mutation; small cell lung carcinoma; nonsquamous non-small cell lung cancer; alveolar soft part sarcoma; malignancy; PD-L1 positive, EGFR-negative, ALK-negative metast NSCLC

Fridge (2-8°C)